Bronchogen vs Vilon
Moderate Research vs Moderate Research
compatible Part of Khavinson bioregulator family; targets different tissue.
Molecular Data
Bronchogen Vilon
Weight 432 Da 275 Da
Half-life Minutes (short peptide); effects persist via epigenetic changes Not established
Chain 4 amino acids 2 amino acids
Type Tetrapeptide bioregulator Dipeptide bioregulator
Key Benefits
Bronchogen
01 Supports bronchial tissue function
02 Regulates protein synthesis in lungs
03 Targets bronchopulmonary system
04 Maintains respiratory epithelium
05 Part of Khavinson bioregulator family
06 Epigenetic mechanism of action
07 Tissue-specific targeting
08 Well-tolerated in research
Vilon
01 Increases mean lifespan 20-40% in animal models
02 Suppresses tumor development
03 Stimulates thymocyte proliferation
04 Activates T-helper cells
05 Restores chromatin structure in aged lymphocytes
06 Enhances intestinal barrier function
07 Improves enzyme activity in aged tissue
08 Part of comprehensive longevity protocols
Dosing Protocols
Bronchogen
10-20 mg oral or 10 mg injectable / Daily for 10-20 days per cycle
Research protocol 10 mg Daily for 10 days
Vilon
10-20 mg per day (oral capsules) or 10 mg (injectable) / Daily for 10-20 consecutive days (Khavinson bioregulator cycle)
Research protocol 10 mg Daily for 10 days
Side Effects
Bronchogen
Generally well-tolerated
Minimal side effects reported
Vilon
Generally well-tolerated
Minimal side effects reported
Contraindications
Active respiratory emergencies (seek medical care)
Known hypersensitivity
Pregnancy or breastfeeding
Active autoimmune flares (consult physician)
Known hypersensitivity
Pregnancy or breastfeeding
Research Evidence
Bronchogen Vilon
Status Moderate Research Moderate Research
References 3 studies 4 studies
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.